Compared with HER2-negative breast cancers, patients with HER2-positive breast cancer now have more favorable prognoses in both early-stage and advanced-stage settings, making HER2-positivity no longer a negative prognostic biomarker.6 Here, ERBB2 is linked to breast carcinoma.